SUNPHARMA · Health Care · 2026-08-21

Sun Pharmaceutical Industries Ltd

4.8WatchEven +1.2Stage 2 · wk 22In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹1,902.4
-0.08% today
₹4,56,449 Cr · Large cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its products to approximately 90 countries across Asia, North America, Europe, Africa, South America, and Australia. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.

Visit company website →
P/E (TTM)
38.5
Forward 28.5
Earnings Growth (YoY)
+25.6%
Revenue +12.8%
ROE
+14.7%
Profit margin +19.6%
Dividend Yield
0.90%
P/B 5.7
vs 52W High
-4.9%
₹1,553.2 lo₹2,001.1 hi
4.9% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 22
1w13w26w
Week 22 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
6.4%
200 DMA: ₹1,788.5 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.71x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -0.8% vs MA50 +2.5%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #43 of 84 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Ranks #34 of 58 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S2 16w
S2 28w
S2 19w
S3 15w
S4 19w
S2 22w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 1w → S2 1w → S1 3w → S2 16w → S3 1w → S2 28w → S3 8w → S2 19w → S3 15w → S4 8w → S1 6w → S4 19w → S1 4w → S2 9w → S3 7w → S2 22w current
Total tracked: 168 weeks across 16 stage runs.
1M
-2.6%
3M
+3.1%
6M
+11.9%
YTD
+11.5%
1Y
+16.8%
Scan Membership
Breakout Watch
Latest: 2026-03-18
3 appearances in last 60 days. First seen: 2024-07-22.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 22 · Vol —x
2026-08-20S2
Wk 22 · Vol —x
2026-08-19S2
Wk 22 · Vol —x
2026-08-18S2
Wk 21 · Vol —x
2026-08-17S2
Wk 21 · Vol —x
2026-08-14S2
Wk 21 · Vol —x
2026-08-13S2
Wk 21 · Vol —x
2026-08-12S2
Wk 21 · Vol —x
2026-08-11S2
Wk 20 · Vol —x
2026-08-10S2
Wk 20 · Vol —x
2026-08-07S2
Wk 20 · Vol —x
2026-08-06S2
Wk 20 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹1,912.6
200 DMA
₹1,788.5
52W High
₹2,001.1
52W Low
₹1,553.2
5D Low
₹1,875.1
Resistance levels (recent highs)
20d High
₹2,001.1
60d High
₹2,001.1
120d High
₹2,001.1
250d High
₹2,001.1
Next resistance
+5.2%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.